January 16, 2015
On 16 January 2015, the UK Competition and Markets Authority (CMA) published its decision unconditionally approving the acquisition of Sauflon Pharmaceuticals Limited by CooperVision (UK) Holdings, Ltd.
Following detailed submissions by the parties, the CMA concluded that the transaction did not result in a realistic prospect of a significant lessening of competition in the UK.
Latham advised CooperVision on the clearance with a London team led by antitrust partner Omar Shah and including partners John Kallaugher and John Colahan and associates Robert Hardy and Calum Warren, as well as competition economists Compass Lexecon led by Neil Dryden. Latham advised CooperVision on the acquisition in July last year, with a team led by London partner Graeme Ward and corporate associates Andrew Clark and Warren Fernandez.